<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> and type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> are associated with elevated circulating levels of insulin, nonesterified fatty acids (NEFAs), and <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> remnants </plain></SENT>
<SENT sid="1" pm="."><plain>Extracellular matrix <z:chebi fb="0" ids="37396">proteoglycan</z:chebi> (PG) alterations are also common in macro- and microvascular complications of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>In liver, extracellular <z:chebi fb="0" ids="24500">heparan</z:chebi> <z:chebi fb="0" ids="16189">sulfate</z:chebi> (HS) PGs contribute to the uptake of <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich <z:chebi fb="1" ids="6495">lipoprotein</z:chebi> remnants </plain></SENT>
<SENT sid="3" pm="."><plain>We found that HepG2 cells cultured with 10 or 50 nmol/l insulin or 300 micromol/l albumin-bound <z:chebi fb="0" ids="17351">linoleic acid</z:chebi> changed their PG secretion </plain></SENT>
<SENT sid="4" pm="."><plain>The <z:chebi fb="0" ids="18085">glycosaminoglycans</z:chebi> (GAGs) of the secreted PGs from insulin-treated HepG2 cells were enriched in <z:chebi fb="0" ids="37397">chondroitin sulfate</z:chebi> (CS) PGs </plain></SENT>
<SENT sid="5" pm="."><plain>In contrast, cells exposed to <z:chebi fb="0" ids="17351">linoleic acid</z:chebi> secreted PGs with decreased content of CS </plain></SENT>
<SENT sid="6" pm="."><plain>Insulin caused a moderate increase in <z:chebi fb="2" ids="33699">mRNA</z:chebi> for versican (secreted CS PG), whereas <z:chebi fb="0" ids="17351">linoleic acid</z:chebi> markedly decreased <z:chebi fb="2" ids="33699">mRNA</z:chebi> for versican in HepG2 cells, as did the peroxisomal proliferator-activated receptor-alpha <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="47612">bezafibrate</z:chebi> </plain></SENT>
<SENT sid="7" pm="."><plain>The effects of insulin or <z:chebi fb="0" ids="17351">linoleic acid</z:chebi> on syndecan 1, a cell surface HS PG, were similar to those on versican, but less pronounced </plain></SENT>
<SENT sid="8" pm="."><plain>The livers of <z:mp ids='MP_0001261'>obese</z:mp> <z:chebi fb="3" ids="16646">Zucker</z:chebi> fa/fa rats, which are insulin-resistant and have high levels of insulin, NEFAs, and <z:chebi fb="0" ids="17855">triglyceride</z:chebi>-rich remnants, showed increased expression of CS PGs when compared with lean littermates </plain></SENT>
<SENT sid="9" pm="."><plain>These changes in PG composition decreased the affinity of remnant beta-<z:chebi fb="1" ids="39027">VLDL</z:chebi> particles to PGs isolated from insulin-treated HepG2 cells and <z:mp ids='MP_0001261'>obese</z:mp> rat livers </plain></SENT>
<SENT sid="10" pm="."><plain>The results indicated that insulin and NEFAs modulate the expression of PGs in hepatic cells </plain></SENT>
<SENT sid="11" pm="."><plain>We speculate that in vivo this exchange of CS for HS may reduce the clearance of remnant beta-<z:chebi fb="1" ids="39027">VLDLs</z:chebi> and contribute to the <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> of <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> </plain></SENT>
</text></document>